UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934.
Date of Report: June 20, 2019
(Date of earliest event reported)
Oragenics, Inc.
(Exact name of registrant as specified in its charter)
| FL | 001-32188 | 59-3410522 | ||
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
||
|
4902 Eisenhower Boulevard, Suite 125 Tampa, FL |
33634 | |||
| (Address of principal executive offices) | (Zip Code) | |||
813-286-7900
(Registrant’s telephone number, including area code)
(Former Name or Former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
||
| Common Stock | OGEN | NYSE American |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.07 |
SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS. |
(a) The 2019 annual meeting of shareholders of Oragenics, Inc. was held on June 20, 2019.
(b) At the 2019 annual meeting, the following proposals were voted on by our shareholders:
PROPOSAL I: Election of Directors.
Dr. Frederick Telling, Dr. Alan Joslyn, Mr. Robert Koski, Mr. Charles Pope, and Dr. Alan Dunton were each re-elected as Directors, to serve until our next annual meeting of shareholders or until their respective successors are elected and qualified or until their earlier resignation, removal from office or death. The votes were as follows:
| For | Withheld |
Broker Non-
Votes |
||||
|
Dr. Frederick Telling |
12,402,122 | 567,518 | 19,882,039 | |||
|
Dr. Alan Joslyn |
12,417,727 | 551,913 | 19,882,039 | |||
|
Robert Koski |
12,378,361 | 591,279 | 19,882,039 | |||
|
Charles Pope |
12,342,871 | 626,769 | 19,882,039 | |||
|
Dr. Alan Dunton |
12,394,501 | 575,139 | 19,882,039 |
PROPOSAL II: To conduct a non-binding advisory vote on the desired frequency of a non-binding advisory vote on executive compensation. The votes were as follows:
|
ONE YEAR |
11,747,310 | |||
|
TWO YEARS |
830,561 | |||
|
THREE YEARS |
131,635 | |||
|
ABSTAIN |
258,234 | |||
|
BROKER NON-VOTES |
19,883,939 |
PROPOSAL III: To conduct a non-binding advisory vote on executive compensation. The votes were as follows:
|
FOR |
11,899,809 | |||
|
AGAINST |
903,997 | |||
|
ABSTAIN |
165,834 | |||
|
BROKER NON-VOTES |
19,882,039 |
PROPOSAL IV: To ratify the 2018 Amendment to the Company’s 2012 Equity Incentive Plan. The votes were as follows:
|
FOR |
11,780,268 | |||
|
AGAINST |
1,123,725 | |||
|
ABSTAIN |
65,647 | |||
|
BROKER NON-VOTES |
19,882,039 |
PROPOSAL V: Approval of an amendment to the Company’s 2012 Equity Incentive Plan. The votes were as follows:
|
FOR |
11,750,832 | |||
|
AGAINST |
1,146,858 | |||
|
ABSTAIN |
71,950 | |||
|
BROKER NON-VOTES |
19,882,039 |
| Item 9.01 |
FINANCIAL STATEMENTS AND EXHIBITS. |
(d) Exhibits
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 21 st day of June, 2019.
| ORAGENICS, INC. | ||
| (Registrant) | ||
| BY: |
/s/ Michael Sullivan |
|
| Michael Sullivan | ||
| Chief Financial Officer | ||
Exhibit 4.5
FOURTH AMENDMENT TO
AMENDED AND RESTATED
ORAGENICS, INC.
2012 EQUITY INCENTIVE PLAN
This Fourth Amendment to the Amended and Restated 2012 Equity Incentive Plan (the “2012 Incentive Plan” ) is made pursuant to Section 12 of the 2012 Incentive Plan.
Recitals:
WHEREAS, the 2012 Incentive Plan was originally adopted by the Company on August 6, 2012 and approved by the shareholders on October 23, 2012; and
WHEREAS, the Board of Directors believes it would be in the best interest of the Company and its shareholders to increase the authorized shares available under the 2012 Incentive Plan.
NOW THEREFORE, Section 4 titled “SHARES SUBJECT TO PLAN” is hereby amended as follows:
The reference to “2,250,000” is replaced with “8,250,000”, to reflect an increase in the shares reserved for use under the 2012 Incentive Plan.
All other terms and conditions of the 2012 Incentive Plan not otherwise modified hereby shall remain in full force and effect. The Amendment was approved by the Board of Directors on April 25, 2019 and submitted to the Company’s shareholders for approval in connection with the Company’s June 20, 2019 Annual Meeting of Shareholders.